GlobeNewsWire
03 Aug 2026, 20:35 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Apnimed's New Drug Application for AD109 has been assigned a PDUFA goal date of February 28, 2027. — A PDUFA date is a critical regulatory milestone that provides a concrete timeline for potential FDA approval, the primary driver of value for clinical-stage biotech.
+0.60Apnimed closed an upsized IPO, raising gross proceeds of $220.8 million. — Substantial capital infusion reduces immediate financing risk and provides the runway necessary to reach the PDUFA date and initial commercialization.
+0.40The lead product candidate AD109 has completed two Phase 3 clinical trials for treating mild, moderate, and severe obstructive sleep apnea. — Completion of Phase 3 indicates the drug is in the final stage of development, lowering the clinical failure risk compared to earlier-stage assets.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company successfully closed an upsized initial public offering, raising $220.8 million in gross proceeds.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
10h ago
